文献速递癫痫

口服奎尼丁治疗KCNT1突变相关癫痫的随机试验

Precision therapy for epilepsy due to KCNT1 mutations: A randomized trial of oral quinidine.
PubMed 文献 · Neurology · 2017-12-01

这项单中心、住院、顺序随机、盲法、安慰剂对照交叉试验纳入6例KCNT1突变所致严重常染色体显性夜间额叶癫痫(ADNFLE)患者,评估口服奎尼丁的疗效。4例完成300 mg/d治疗,奎尼丁未显著减少发作频率(中位数变化2次/日,95%CI -1.5至+5,p=0.15),且900和600 mg/d时出现QT间期延长。结论提示奎尼丁在ADNFLE中无效且伴心脏风险。

要点

  • 奎尼丁未显著减少KCNT1突变ADNFLE患者的发作频率。
  • 900和600 mg/d剂量下出现QT间期延长,即使血清浓度低于治疗范围。
  • 完成试验的4例患者使用300 mg/d未出现不良事件。

核心结论

  • 奎尼丁在成人和青少年ADNFLE患者中未显示疗效。
  • 奎尼丁使用伴随显著心脏风险,即使血清浓度较低。
  • 该试验提示奎尼丁治疗ADNFLE可能无效且风险较高。

研究设计与样本

  • 单中心、住院、顺序随机、盲法、安慰剂对照交叉试验。
  • 纳入6例KCNT1突变所致严重ADNFLE患者。
  • 采用4天治疗块,间隔2天洗脱期,剂量从900 mg/d(分3次)降至600 mg/d、300 mg/d。
  • 主要结局为完成试验者通过连续视频脑电图测定的发作频率。

主要发现

  • 前2例患者在900和600 mg/d剂量下出现QT间期延长,血清奎尼丁浓度分别为0.61和0.51 μg/mL(参考范围1.3-5.0 μg/mL)。
  • 4例患者完成300 mg/d治疗且无不良事件。
  • 完成试验的患者发作频繁(均值14次/日,标准差7,中位数13,四分位距10-18)。
  • 奎尼丁使每日发作次数非显著增加(中位数2,95%CI -1.5至+5,p=0.15)。
  • 无患者达到50%发作减少。

关键数值与推荐

  • 主要结局:每日发作次数变化中位数2,95%CI -1.5至+5,p=0.15。
  • 血清奎尼丁治疗参考范围1.3-5.0 μg/mL。
  • 剂量限制性心脏副作用在900和600 mg/d时观察到。

临床怎么用

  • 对于KCNT1功能获得突变所致ADNFLE,奎尼丁可能无效且不应作为精准治疗常规使用。
  • 使用奎尼丁需监测QT间期和血清浓度,即使低浓度也可能出现心脏副作用。

局限性

  • 样本量小(仅6例入组,4例完成)。
  • 研究仅纳入成人和青少年ADNFLE患者。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To evaluate quinidine as a precision therapy for severe epilepsy due to gain of function mutations in the potassium channel gene KCNT1. METHODS: A single-center, inpatient, order-randomized, blinded, placebo-controlled, crossover trial of oral quinidine included 6 patients with severe autosomal dominant nocturnal frontal lobe epilepsy (ADNFLE) due to KCNT1 mutation. Order was block randomized and blinded. Four-day treatment blocks were used with a 2-day washout between. Dose started at 900 mg over 3 divided doses then, in subsequent participants, was reduced to 600 mg, then 300 mg. Primary outcome was seizure frequency measured on continuous video-EEG in those completing the trial. RESULTS: Prolonged QT interval occurred in the first 2 patients at doses of 900 and 600 mg quinidine per day, respectively, despite serum quinidine levels well below the therapeutic range (0.61 and 0.51 μg/mL, reference range 1.3-5.0 μg/mL). Four patients completed treatment with 300 mg/d without adverse events. Patients completing the trial had very frequent seizures (mean 14 per day, SD 7, median 13, interquartile range 10-18). Seizures per day were nonsignificantly increased by quinidine (median 2, 95% confidence interval -1.5 to +5, p = 0.15) and no patient had a 50% seizure reduction. CONCLUSION: Quinidine did not show efficacy in adults and teenagers with ADNFLE. Dose-limiting cardiac side effects were observed even in the presence of low measured serum quinidine levels. Although small, this trial suggests use of quinidine in ADNFLE is likely to be ineffective coupled with considerable cardiac risks. CLINICAL TRIALS REGISTRATION: Australian Therapeutic Goods Administration Clinical Trial Registry (trial number 2015/0151). CLASSIFICATION OF EVIDENCE: This study provides Class II evidence that for persons with severe epilepsy due to gain of function mutations in the potassium channel gene KCNT1, quinidine does not significantly reduce seizure frequency.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. Mullen SA, Carney PW, Roten A, et al. Precision therapy for epilepsy due to KCNT1 mutations: A randomized trial of oral quinidine. Neurology. 2017. PMID: 29196578. doi:10.1212/WNL.0000000000004769

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。